Title:
癌治療剤
Document Type and Number:
Japanese Patent JP5885764
Kind Code:
B2
Abstract:
Compositions for cancer or infection treatment via immunopotentiation caused by inhibition of immunosuppressive signal induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient, screening methods of the substrates for cancer or infection treatment, cell lines used for the screening methods, evaluation methods that selects the substrates for cancer treatment, and carcinoma cell transplanted mammals used for the evaluation methods. The compositions of the present invention that inhibits the function of PD-1, PD-L1, or PD-L2 are useful for cancer or infection treatment,
More Like This:
Inventors:
Tasuku Honjo
Nagahiro Minato
Yoshiko Iwai
Shiro Shibayama
Nagahiro Minato
Yoshiko Iwai
Shiro Shibayama
Application Number:
JP2014007941A
Publication Date:
March 15, 2016
Filing Date:
January 20, 2014
Export Citation:
Assignee:
Ono Pharmaceutical Co., Ltd.
Tasuku Honjo
Tasuku Honjo
International Classes:
A61K39/395; A61K31/7088; A61K35/14; A61K38/21; A61K39/00; A61K45/00; A61P31/00; A61P35/00; A61P35/04; A61P37/04; A61P43/00; C07K16/42; C12N15/02; C12P21/08; C12Q1/02; G01N33/50; G01N33/574
Foreign References:
| WO2001014557A1 | ||||
| WO2002000730A1 | ||||
| WO2002000692A1 |
Other References:
TAMURA, H. et al,B7-H1 costimulation preferentially enhances CD28-independent T-helper cell function,Blood,2001年,vol.97, no.6,pages 1809-1816
Nature Medicine,2002年 6月,Vol.8,p.793-800
FASEB Journal,2002年 4月,Vol.16, No.4,A710 517.4
Nature Medicine,2002年 6月,Vol.8,p.793-800
FASEB Journal,2002年 4月,Vol.16, No.4,A710 517.4
Attorney, Agent or Firm:
Atsushi Aoki
Takashi Ishida
Fukumoto product
Tetsuji Koga
Yoichi Watanabe
Ryotaro Takei
Masaru Nakajima
Takashi Ishida
Fukumoto product
Tetsuji Koga
Yoichi Watanabe
Ryotaro Takei
Masaru Nakajima